Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AFIC Celebrates FAO World Milk Day On June 1st
The World Milk Day provides an opportunity to focus attention on milk and to publicise activities connected with milk and the milk industry. The fact that many countries choose to do this on the same day lends additional importance to individual national celebrations and shows that milk is a global food.
generic viagra online
Diets High In Calcium And Dairy Products In Childhood May Lower Mortality
New evidence suggests that children who have a diet high in calcium and who consume dairy products may have a lower mortality rate compared with those who do not, according to research published ahead of print in the journal Heart.
News of the day
Action Needed To Realise The Potential Of New Genetic Studies
New studies that analyse genetic differences across thousands of human genomes
Public Health

International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells

International Stem Cell Corporation (OTCBB:ISCO), the first company to perfect a method of creating human "parthenogenetic" stem cells from unfertilized eggs, has received positive early results from animal trials designed to improve photorefractive keratectomy (PRK), a form of corrective laser eye surgery that offers an improved alternative to LASIK. PRK is generally thought to be safer and produce better long-term results than LASIK, but has not been used as frequently because of patient discomfort following surgery and a longer healing time. By combining ISCO"s human corneal cells with a proprietary surgical device developed by Paul H. Chen, M.D., who is conducting the trials, ISCO and Dr. Chen believe that cellular enhanced PRK can replace LASIK for many of the hundreds of thousands of patients who now use LASIK. The first stage animal trials just completed demonstrated that ISCO"s corneal cells manufactured by ISCO"s subsidiary, Lifeline Cell Technology, encouraged corneal-defect healing in the animals. The trials are the first step toward gaining Food and Drug Administration (FDA) approval to test the efficacy of using ISCO"s cells to improve healing after corneal surgery, and could result in the first FDA approved use of human cells produced by ISCO. Jeffrey Janus, President of ISCO and CEO of Lifeline, noted that "The cells used in these trials are derived from donated human tissue processed using proprietary techniques devised by ISCO"s subsidiary, Lifeline Cell Technology. However, ISCO"s parthenogenic stem cells can also produce human corneal cells. Corneal cells derived from ISCO"s parthenogenetic stem cells may provide a consistent and reliable of corneal cells that could eliminate entirely the need for donated human tissues." This work is being done in collaboration with Dr. Chen, who has developed the cell transfer technology. Dr. Chen is an eye surgeon at North County Laser Eye Associates, and he is on staff at Scripps Memorial La Jolla and Scripps Encinitas Hospitals. For more news and information on International Stem Cell Corporation please visit http://www.IRGnews.com/coi/ISCO where you can find the CEO"s video, a fact sheet on the company, investor presentations, and more. International Stem Cell Corporation (ISCO.OB)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009